The BioNTech SE ADR BNTX rose 4.79% to $118.47 Tuesday, on what proved to be an all-around great trading session for the ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

The autumn wave of coronavirus is sweeping across Germany. Those affected mainly suffer from coughs, colds, sore throats and ...

Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...

The decision not to advance the vaccine into Phase III trials effectively ends GSK's ambition to bring the first HSV vaccine ...

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...

BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...

Discover BioNTech SE's innovative RNA lipoplex patent, detailing advanced methods for stable RNA delivery, GMP production, and effective intravenous administration.

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

The BioNTech SE ADR BNTX inched 0.69% higher to $113.05 Monday, on what proved to be an all-around positive trading session ...